Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Free Report) shares fell 5.3% during trading on Friday . The company traded as low as $32.52 and last traded at $33.1350. 241,294 shares changed hands during trading, a decline of 32% from the average session volume of 354,785 shares. The stock had previously closed at $35.00.
Wall Street Analyst Weigh In
A number of research firms have recently commented on ETON. B. Riley Financial upped their target price on Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, March 20th. Zacks Research lowered Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, April 17th. HC Wainwright increased their price objective on Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a report on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Wall Street Zen upgraded Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eton Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $41.00.
View Our Latest Stock Report on ETON
Eton Pharmaceuticals Price Performance
Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). The company had revenue of $24.27 million during the quarter, compared to analysts’ expectations of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. As a group, equities research analysts expect that Eton Pharmaceuticals, Inc. will post 0.82 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Opaleye Management Inc. lifted its stake in Eton Pharmaceuticals by 0.3% in the 2nd quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock worth $40,755,000 after purchasing an additional 7,930 shares in the last quarter. EcoR1 Capital LLC increased its holdings in Eton Pharmaceuticals by 7.0% in the 1st quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock valued at $53,603,000 after purchasing an additional 141,394 shares during the last quarter. Vanguard Group Inc. increased its holdings in Eton Pharmaceuticals by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock valued at $29,208,000 after purchasing an additional 31,942 shares during the last quarter. State Street Corp increased its holdings in Eton Pharmaceuticals by 14.5% in the 4th quarter. State Street Corp now owns 501,925 shares of the company’s stock valued at $8,488,000 after purchasing an additional 63,480 shares during the last quarter. Finally, Cannell Capital LLC grew its stake in shares of Eton Pharmaceuticals by 17.3% in the third quarter. Cannell Capital LLC now owns 455,405 shares of the company’s stock worth $9,896,000 after acquiring an additional 67,230 shares in the last quarter. 27.86% of the stock is owned by hedge funds and other institutional investors.
Eton Pharmaceuticals Company Profile
Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.
The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.
Read More
- Five stocks we like better than Eton Pharmaceuticals
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
